Approval · Notice of Compliance 28068 · 2022
DIFFERIN: Notice of Compliance 28068
Issued May 2, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28068
- Date
- May 2, 2022
- Company
- Galderma Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing site and/or manufacturer involving the production of the drug substance adapalene.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DIFFERIN | Not yet assigned | — |
| DIFFERIN XP | Not yet assigned | — |